A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans
Bacteriophages (phages) may constitute a natural, safe, and effective strategy to prevent and control multidrug-resistant organisms (MDROs), and ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) path...
Gespeichert in:
Veröffentlicht in: | Clinical infectious diseases 2019-06, Vol.69 (1), p.167-178 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 178 |
---|---|
container_issue | 1 |
container_start_page | 167 |
container_title | Clinical infectious diseases |
container_volume | 69 |
creator | El Haddad, Lynn Harb, Cynthia P. Gebara, Marc A. Stibich, Mark A. Chemaly, Roy F. |
description | Bacteriophages (phages) may constitute a natural, safe, and effective strategy to prevent and control multidrug-resistant organisms (MDROs), and ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens in particular. Few clinical studies have assessed the safety and efficacy of phages in patients infected with MDROs. This systematic review summarizes and critically evaluates published studies of phages in clinical practice and presents the appropriate phage selection criteria, as well as recommendations for clinicians and scientists for a successful therapy. Articles were identified through a search of the PubMed, Ovid, EMBASE, and Cochrane Library databases. Among 1102 articles and abstracts, 30 studies were selected and evaluated using selective inclusion criteria, phage criteria, and study characteristics. Most studies showed efficacy (87%) and safety (67%) of the tested phages, but few studies examined phage resistance (35%). Clinical studies and regulatory changes are needed to determine the safety and efficacy of phages and to advance their use in patients with MDRO infections. |
doi_str_mv | 10.1093/cid/ciy947 |
format | Article |
fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2130060634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26794913</jstor_id><oup_id>10.1093/cid/ciy947</oup_id><sourcerecordid>26794913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-9cd72d0d838027cae39006e8364b9b3d6a57dd518a1028000d8cbdc0f5b9f3043</originalsourceid><addsrcrecordid>eNp90MtLAzEQBvAgiu-LdyUXQYTVyWZfOdZSrVip2Hpeskm2RvZlklX63xvZ2qOHYebw42P4EDojcEOA0VuhpZ81i9IddEhimgZJzMiuvyHOgiij2QE6svYDgJAM4n10QIGymKTsEHUjvFhbp2rutMC8kXhstD95hV_Vl1bfuC3xHRdOGd1273yl8PJdGd6t8WjFdWMdfu4rp6XpV4FRVlvHG4cni6fRywTPzYo32tYW6wZP-5o39gTtlbyy6nSzj9Hb_WQ5ngaz-cPjeDQLBKXMBUzINJQg_fMQpoIrygASldEkKlhBZcLjVMqYZJxAmAF4KQopoIwLVlKI6DG6GnI70372yrq81laoquKNanubh4T6QEjoL70eqDCttUaVeWd0zc06J5D_Npz7hvOhYY8vNrl9USu5pX-VenA5gLbv_g86H9yHda3ZyjBJWcQIpT9o5Y4J</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2130060634</pqid></control><display><type>article</type><title>A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>El Haddad, Lynn ; Harb, Cynthia P. ; Gebara, Marc A. ; Stibich, Mark A. ; Chemaly, Roy F.</creator><creatorcontrib>El Haddad, Lynn ; Harb, Cynthia P. ; Gebara, Marc A. ; Stibich, Mark A. ; Chemaly, Roy F.</creatorcontrib><description>Bacteriophages (phages) may constitute a natural, safe, and effective strategy to prevent and control multidrug-resistant organisms (MDROs), and ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens in particular. Few clinical studies have assessed the safety and efficacy of phages in patients infected with MDROs. This systematic review summarizes and critically evaluates published studies of phages in clinical practice and presents the appropriate phage selection criteria, as well as recommendations for clinicians and scientists for a successful therapy. Articles were identified through a search of the PubMed, Ovid, EMBASE, and Cochrane Library databases. Among 1102 articles and abstracts, 30 studies were selected and evaluated using selective inclusion criteria, phage criteria, and study characteristics. Most studies showed efficacy (87%) and safety (67%) of the tested phages, but few studies examined phage resistance (35%). Clinical studies and regulatory changes are needed to determine the safety and efficacy of phages and to advance their use in patients with MDRO infections.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciy947</identifier><identifier>PMID: 30395179</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>REVIEW ARTICLE</subject><ispartof>Clinical infectious diseases, 2019-06, Vol.69 (1), p.167-178</ispartof><rights>The Author(s) 2019</rights><rights>The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2019</rights><rights>The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-9cd72d0d838027cae39006e8364b9b3d6a57dd518a1028000d8cbdc0f5b9f3043</citedby><cites>FETCH-LOGICAL-c339t-9cd72d0d838027cae39006e8364b9b3d6a57dd518a1028000d8cbdc0f5b9f3043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,1579,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30395179$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>El Haddad, Lynn</creatorcontrib><creatorcontrib>Harb, Cynthia P.</creatorcontrib><creatorcontrib>Gebara, Marc A.</creatorcontrib><creatorcontrib>Stibich, Mark A.</creatorcontrib><creatorcontrib>Chemaly, Roy F.</creatorcontrib><title>A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Bacteriophages (phages) may constitute a natural, safe, and effective strategy to prevent and control multidrug-resistant organisms (MDROs), and ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens in particular. Few clinical studies have assessed the safety and efficacy of phages in patients infected with MDROs. This systematic review summarizes and critically evaluates published studies of phages in clinical practice and presents the appropriate phage selection criteria, as well as recommendations for clinicians and scientists for a successful therapy. Articles were identified through a search of the PubMed, Ovid, EMBASE, and Cochrane Library databases. Among 1102 articles and abstracts, 30 studies were selected and evaluated using selective inclusion criteria, phage criteria, and study characteristics. Most studies showed efficacy (87%) and safety (67%) of the tested phages, but few studies examined phage resistance (35%). Clinical studies and regulatory changes are needed to determine the safety and efficacy of phages and to advance their use in patients with MDRO infections.</description><subject>REVIEW ARTICLE</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp90MtLAzEQBvAgiu-LdyUXQYTVyWZfOdZSrVip2Hpeskm2RvZlklX63xvZ2qOHYebw42P4EDojcEOA0VuhpZ81i9IddEhimgZJzMiuvyHOgiij2QE6svYDgJAM4n10QIGymKTsEHUjvFhbp2rutMC8kXhstD95hV_Vl1bfuC3xHRdOGd1273yl8PJdGd6t8WjFdWMdfu4rp6XpV4FRVlvHG4cni6fRywTPzYo32tYW6wZP-5o39gTtlbyy6nSzj9Hb_WQ5ngaz-cPjeDQLBKXMBUzINJQg_fMQpoIrygASldEkKlhBZcLjVMqYZJxAmAF4KQopoIwLVlKI6DG6GnI70372yrq81laoquKNanubh4T6QEjoL70eqDCttUaVeWd0zc06J5D_Npz7hvOhYY8vNrl9USu5pX-VenA5gLbv_g86H9yHda3ZyjBJWcQIpT9o5Y4J</recordid><startdate>20190618</startdate><enddate>20190618</enddate><creator>El Haddad, Lynn</creator><creator>Harb, Cynthia P.</creator><creator>Gebara, Marc A.</creator><creator>Stibich, Mark A.</creator><creator>Chemaly, Roy F.</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190618</creationdate><title>A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans</title><author>El Haddad, Lynn ; Harb, Cynthia P. ; Gebara, Marc A. ; Stibich, Mark A. ; Chemaly, Roy F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-9cd72d0d838027cae39006e8364b9b3d6a57dd518a1028000d8cbdc0f5b9f3043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>REVIEW ARTICLE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El Haddad, Lynn</creatorcontrib><creatorcontrib>Harb, Cynthia P.</creatorcontrib><creatorcontrib>Gebara, Marc A.</creatorcontrib><creatorcontrib>Stibich, Mark A.</creatorcontrib><creatorcontrib>Chemaly, Roy F.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El Haddad, Lynn</au><au>Harb, Cynthia P.</au><au>Gebara, Marc A.</au><au>Stibich, Mark A.</au><au>Chemaly, Roy F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2019-06-18</date><risdate>2019</risdate><volume>69</volume><issue>1</issue><spage>167</spage><epage>178</epage><pages>167-178</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Bacteriophages (phages) may constitute a natural, safe, and effective strategy to prevent and control multidrug-resistant organisms (MDROs), and ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens in particular. Few clinical studies have assessed the safety and efficacy of phages in patients infected with MDROs. This systematic review summarizes and critically evaluates published studies of phages in clinical practice and presents the appropriate phage selection criteria, as well as recommendations for clinicians and scientists for a successful therapy. Articles were identified through a search of the PubMed, Ovid, EMBASE, and Cochrane Library databases. Among 1102 articles and abstracts, 30 studies were selected and evaluated using selective inclusion criteria, phage criteria, and study characteristics. Most studies showed efficacy (87%) and safety (67%) of the tested phages, but few studies examined phage resistance (35%). Clinical studies and regulatory changes are needed to determine the safety and efficacy of phages and to advance their use in patients with MDRO infections.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>30395179</pmid><doi>10.1093/cid/ciy947</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1058-4838 |
ispartof | Clinical infectious diseases, 2019-06, Vol.69 (1), p.167-178 |
issn | 1058-4838 1537-6591 |
language | eng |
recordid | cdi_proquest_miscellaneous_2130060634 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
subjects | REVIEW ARTICLE |
title | A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A07%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Systematic%20and%20Critical%20Review%20of%20Bacteriophage%20Therapy%20Against%20Multidrug-resistant%20ESKAPE%20Organisms%20in%20Humans&rft.jtitle=Clinical%20infectious%20diseases&rft.au=El%20Haddad,%20Lynn&rft.date=2019-06-18&rft.volume=69&rft.issue=1&rft.spage=167&rft.epage=178&rft.pages=167-178&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciy947&rft_dat=%3Cjstor_proqu%3E26794913%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2130060634&rft_id=info:pmid/30395179&rft_jstor_id=26794913&rft_oup_id=10.1093/cid/ciy947&rfr_iscdi=true |